Compare PXS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXS | HOWL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 46.7M |
| IPO Year | 2015 | 2021 |
| Metric | PXS | HOWL |
|---|---|---|
| Price | $4.89 | $0.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 78.5K | ★ 405.8K |
| Earning Date | 11-30-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.84 | N/A |
| Revenue Next Year | $2.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.67 | $0.27 |
| 52 Week High | $8.34 | $1.20 |
| Indicator | PXS | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 26.14 | 41.24 |
| Support Level | $3.98 | $0.88 |
| Resistance Level | $8.32 | $0.99 |
| Average True Range (ATR) | 0.44 | 0.06 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 10.89 | 0.00 |
Pyxis Tankers Inc is an international maritime transportation company focused on mid-sized eco-vessels for the product tanker and dry-bulk sectors. It owns a fleet that comprises double-hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Konkar Ormi, Pyxis Lamda, Konkar Venture, Pyxis Karteria, and others. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals. The company operates under two reportable segments, Tanker Vessels, which derive maximum revenue, and Dry-bulk Vessels.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.